Phase 3 trial results show combined ixekizumab and tirzepatide therapy outperforms ixekizumab alone for patients with psoriasis and obesity or overweight.

Remibrutinib shows significant complete response rates across 3 chronic inducible urticaria subtypes in the phase 3 RemIND trial.

Patients in the pediatric intensive care unit who received high-risk rounds were less likely to incur a hospital-acquired condition.

Reinstatement of Medicare's 3-day hospitalization requirement increased inpatient stays, without reducing SNF utilization.

President Donald Trump rescinded the EPA's endangerment finding, which allowed for federal regulations on pollution to protect public health.

Increasing applications of HCCP among patients with postherpetic neuralgia were associated with increasing improvements in outcomes at 12 months.

Real-world study results showed that sonidegib was associated with greater treatment persistence than vismodegib at 12 months among adults with BCC.

Increased numbers of state-level abortion restrictions were associated with measurable rises in maternal mortality.

Dupilumab was safe and effective for the treatment of patients with severe AD who were aged 6 months to 5 years in a real-world study.

Several factors have been identified that may predict super response or refractory response to rituximab among patients with pemphigus.

The table below is a review of notable updates that occurred in January 2026 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

A proposed Oregon law aimed to cap THC in individual cannabis servings at 10 mg, following high rates of pediatric poisonings in 2023.